Cochrane Abstracts
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rituximab, Ofatumumab and Other Monoclonal anti‐CD20 Antibodies for Chronic Lymphocytic Leukaemia." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Rituximab__ofatumumab_and_other_monoclonal_anti‐CD20_antibodies_for_chronic_lymphocytic_leukaemia.
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Rituximab__ofatumumab_and_other_monoclonal_anti‐CD20_antibodies_for_chronic_lymphocytic_leukaemia. Accessed December 5, 2025.
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Rituximab__ofatumumab_and_other_monoclonal_anti‐CD20_antibodies_for_chronic_lymphocytic_leukaemia
Rituximab, Ofatumumab and Other Monoclonal anti‐CD20 Antibodies for Chronic Lymphocytic Leukaemia [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 December 05]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Rituximab__ofatumumab_and_other_monoclonal_anti‐CD20_antibodies_for_chronic_lymphocytic_leukaemia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia
ID - 437054
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Rituximab__ofatumumab_and_other_monoclonal_anti‐CD20_antibodies_for_chronic_lymphocytic_leukaemia
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
